Chen, Tianle
Biogen (United States)
4 papers on CoChatORCID 0009-0000-5930-0145
Most cited papers
- Verified
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 3,059
- Verified
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
Budd Haeberlein, S., Aisen, P. S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., et al. (2022) · The Journal of Prevention of Alzheimer's Disease
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 1,367
- Verified
Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2017) · Nature
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 83
- Verified
Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease: Developments in clinical trials and cognitive assessment
Haeberlein, S. B., von Hehn, C., Tian, Y., Chalkias, S., Muralidharan, K. K., Chen, T., Wu, S., Skordos, L., Nisenbaum, L., Rajagovindan, R., et al. (2020) · Alzheimer's & Dementia
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research
Cited by 81
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free